FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average acquisition cost for dozens of specialty generic drugs, bringing in more than $7.

Adjusted per-share earnings in the fourth quarter for UnitedHealth top analysts’ estimates but revenue comes up short.

The UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases the cost of such medication exponentially.

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension drug.

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands of percent.

They accuse the company of forming agreements with insurers—UnitedHealth Group, Elevance Health, Aetna and Cigna are listed as "co-conspirators"—to set out-of-network prices using a common ...

But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it had made less than analysts expected.

UnitedHealth Group’s upcoming earnings call marks the company's first public appearance since the murder of UnitedHealthcare CEO Brian Thompson.

UnitedHealth Group (NYSE:UNH) reported the fourth-quarter 2024 earnings and reaffirmed 2025 guidance. The company reported adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.

Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.

UnitedHealth Group is charging patients a markup for key ... The report, which levels the same allegations at CVS and Cigna, is the latest indictment of America’s broken healthcare system ...